Background {#Sec1}
==========

Elderly patients represent an increasing percentage of the population undergoing percutaneous coronary interventions (PCI) \[[@CR1]\]. This trend is due, in part, to a prolonged life expectancy and better access to medical care. However, advanced age is associated with poor outcomes in patients with acute coronary syndromes (ACS), stable coronary artery disease (CAD) treated with PCI and bypass surgery as well as in patients with heart failure \[[@CR2]--[@CR4]\]. Elderly patients undergoing PCI have a significantly higher burden of comorbidities.

When compared with younger patients, they less often receive guideline-recommended adjunctive therapies \[[@CR2]\], and invasive treatment with drug-eluting stents (DES) implantation \[[@CR5], [@CR6]\]. Moreover, these patients are often excluded from randomized clinical trials which perhaps could elucidate optimal therapies and risk assessments that would reduce complication specific to this population \[[@CR7], [@CR8]\]. Furthermore, there are limited data on the impact of the DES types (first vs. second generation: DES-I vs. DES-II) on PCI outcomes in the elderly. The primary goal of this present study was to evaluate the effect of age on the risk of major adverse cardiovascular events at 12-month follow-up in patients treated with DES. The secondary goal was to compare the impact of DES types on the observed outcome in these elderly patients.

Methods and study population {#Sec2}
============================

The Katowice--Zabrze registry contains data that included 1916 patients treated with either first- (paclitaxel and sirolimus eluting; 33.6%) or second-generation (everolimus, zotarolimus, biolimus A9 eluting, 66.4%) DES in two tertiary Silesian cardiology centers. We obtained and recorded retrospective data which included baseline characteristics, cardiac history, risk factors, medications, angiographic and procedural data. For our study, we defined patients ≥70 years of age as elderly. Angiographic data were collected in all patients undergoing PCI and recorded in the cardiovascular information registry. SYNTAX scores were calculated for all patients except these with prior CABG (coronary artery bypass graft). For patients with the occluded infarct-related artery, SYNTAX scores were calculated based on baseline angiography. Two observers estimated the SYNTAX scores, in cases where the SYNTAX score consensus could not be made; the angiography was excluded from this analysis. The primary efficacy endpoint was a composite of major adverse cardiac and cerebral events (MACCE), including all-cause death, non-fatal myocardial infarction (MI), target vessel revascularization (TVR), and stroke during the in-hospital stay and at 12-month follow-up. The secondary endpoints were individual components of the primary endpoint (all-cause death, MI, TVR, stroke) and in-hospital bleeding complications. The safety of DES was defined as definite stent thrombosis (acute, subacute, late). TVR, definite stent thrombosis, acute, subacute and late stent thrombosis were defined according to the definitions of endpoints for clinical trials \[[@CR9]\]. Gastrointestinal bleeding was considered an endpoint if it fulfilled criteria for type 3 or type 5 bleeding complication according to proposed definitions \[[@CR10]\]. Data regarding outcomes (MACCE and gastrointestinal bleeding) at 12-month were obtained from the database of the National Health Fund Service (Ministry of Health).

Statistics {#Sec3}
==========

Statistical analysis was performed using MedCalc Software (v.12 Belgium). Continuous data were presented as mean ± standard deviation and median with interquartile range (Q1--Q3). Qualitative data were expressed as crude values and/or percentages. Between-group differences for quantitative variables were assessed using Mann--Whitney U test for non-normally distributed data and one-way ANOVA for normally distributed data. Chi-square test was used for qualitative variables. Data distribution was verified with Smirnov--Kolmogorov test. The univariable analysis was performed to determine the risk factors for death at 12-month follow-up. Variables with *p* values less than 0.05 entered the multivariate analysis model to estimate independent risk factors of death at 12-month follow-up. Kaplan--Meier curves were used to present the unadjusted time-to-event data for investigated end-points. A value of 2-tailed *p* \< 0.05 was considered significant.

Results {#Sec4}
=======

The registry included 1916 patients referred for PCI because of unstable angina (UA) \[1500 (78.2%)\], non-ST-segment elevation myocardial infarction (NSTEMI) \[285 (14.8%)\] and ST-segment elevation myocardial infarction (STEMI/LBBB) \[131(6.8%)\] (Table [1](#Tab1){ref-type="table"}). Five hundred sixty-three patients (29.4%) were ≥70 years of age compared to one thousand, three hundred and fifty-three patients (70.6%) ≤70 years of age. There were fewer men in the elderly group, and elderly patients had a higher prevalence of hypertension, diabetes, chronic kidney disease, anemia, chronic obstructive pulmonary disease, carotid artery disease and neoplasm, as compared to the younger group. The elderly patients were more often hospitalized because of NSTEMI and had a higher prevalence of GRACE risk score over 140. The length of hospital stay was also longer in elderly patients (5.0 IQR 4--7 vs. 4.0 IQR 3--6, *p* \< 0.001). Younger patients had more dyslipidemia, family history of CAD, and were more often current smokers. There were no differences regarding the history of myocardial infarction, previous PCI and CABG between the elderly and younger patients' groups. Elderly patients had a lower LVEF (50% IQR 44.0--58.0 vs. 55% IQR 46.0--60.0; *p* = 0.001) when compared to the younger group (Table [1](#Tab1){ref-type="table"}).Table 1Patients characteristics, risk factors and clinical presentation according to the ageAge \<70\
*n* = 1353 (70.6%)Age ≥70\
*n* = 563 (29.4%)*p*Demographic data Male, *n* (%)944 (69.7)292 (51.8)\<0.001 BMI (kg/m^2^), median (IQR)28.7 (25.8--31.6)28.4 (25.5--31.4)0.623Discharge diagnosis UA, *n* (%)1074 (79.4)426 (75.6)0.082 NSTEMI, *n* (%)178 (13.2)107 (19.0)0.001 STEMI/LBBB, *n* (%)101 (7.5)30 (5.3)0.112CAD history Previous MI, *n* (%)638 (47.2)277 (49.2)0.443 Previous PCI, *n* (%)744 (55.0)320 (56.8)0.489 Previous CABG, *n* (%)277 (20.5)121 (21.4)0.660CAD risk factors Hypertension, *n* (%)1137 (84.0)506 (89.9)0.001 Dyslipidemia, *n* (%)946 (69.9)318 (56.5)\<0.001 CKD, *n* (%)141 (10.4)190 (33.7)\<0.001 Anemia, *n* (%)113 (8.4)104 (18.5)\<0.001 Diabetes mellitus, *n* (%)440 (32.5)277 (49.2)\<0.001 Current smoking, *n* (%)418 (30.9)46 (8.2)\<0.001 Family history of CAD, *n* (%)501 (37.0)127 (22.6)\<0.001Concomitant disease Cancer, *n* (%)63 (4.7)54 (9.6)\<0.001 COPD, *n* (%)64 (4.7)53 ( (9.4)\<0.001 PAD, *n* (%)147 (10.9)71 (12.6)0.308 Carotid artery disease, *n* (%)64 (4.7)49 (8.7)0.002 Obesity, *n* (%)319 (23.6)122 (21.7)0.398 Length of hospital stay (day), median (IQR)4.0 (3--6)5.0 (4--7)\<0.001Left ventricular function, *n* (%) \<30%81 (6.0)32 (5.7)0.890 30--50%292 (21.6)162 (28.8)\<0.001 \>50%964 (71.2)361 (64.1)0.002 LVEF, median (IQR)55.0 (46.0--60.0)50.0 (44.0--58.0)0.001Laboratory (on admission) GFR (ml/min/1.73 m^2^), median (IQR)88.2 (73.5--97.3)67.7 (55.1--82.3)\<0.001 Hemoglobin, (g/dl), median (IQR)14.4 (13.5--15.2)13.6 (12.7--14.5)\<0.001Clinical status on admission HR, (bpm), median (IQR)70 (60--80)70 (60--76)0.935 SBP, (mmHg), median (IQR)130 (120--145)140 (125--150)\<0.001 GRACE score \> 140, *n* (%)84 (6.2)52 (9.2)0.007CKD was defined as estimated GFR (eGFR) \<60 60 ml/min/1.73 m^2^ calculated using the modification of diet in renal disease (MDRD) method*BMI* body mass index, *UA* unstable angina, *NSTEMI* non-ST-segment elevation myocardial infarction, *STEMI* ST-segment elevation myocardial infarction, *CAD* coronary artery disease, *MI* myocardial infarction, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass graft, *CKD* chronic kidney disease, *COPD* chronic obstructive pulmonary disease, *PAD* peripheral artery disease, *HR* heart rate, *SBP* systolic blood pressure

Chronic medications {#Sec5}
-------------------

The higher burden of comorbidities observed in the elderly patient population included atrial fibrillation. Therefore, the use of vitamin K antagonists at discharge was higher in the elderly group (Table [2](#Tab2){ref-type="table"}).Table 2Post-procedure drug therapy according to the ageAge \<70\
*n* = 1353 (70.6%)Age ≥70\
*n* = 563 (29.4%)*p*ASA, *n* (%)1335 (98.7)552 (98.0)0.270Clopidogrel, *n* (%)1334 (98.6)555 (98.6)0.988VKA, *n* (%)46 (3.3)47 (8.3)\<0.001Beta-blockers, *n* (%)1220 (90.2)498 (88.5)0.261ACEI, *n* (%)1073 (79.3)442 (78.5)0.706ARB, *n* (%)157 (11.6)73 (13.0)0.453Statins, *n* (%)1260 (93.1)530 (94.1)0.524Ca-blockers, *n* (%)337 (24.9)186 (33.0)\<0.001Prasugrel, *n* (%)4 (0.3)1 (0.2)0.976*ASA* acetylsalicylic acid, *VKA* vitamin K antagonists, *ACEI* angiotensin-converting-enzyme inhibitor, *ARB* angiotensin receptor blocker, *Ca-blockers* calcium channel blockers

Interventional treatment and reperfusion strategy {#Sec6}
-------------------------------------------------

There was a trend for a higher SYNTAX score in our elderly patients (15 IQR 8--26 vs. 14 IQR 8--22; *p* = 0.08). As well, our elderly patients had more multivessel diseases. As shown in Table [3](#Tab3){ref-type="table"}, first- and second-generation DES was used with similar frequency in both groups of patients.Table 3Angiographic and procedural data according to the ageAge \<70\
*n* = 1353 (70.6%)Age ≥70\
*n* = 563 (29.4%)*p*SYNTAX score, median (IQR)14 (8--22)15 (8--26)0.082DES-I, *n* (%)454 (33.6)191 (33.9)0.917DES-II, *n* (%)899 (66.4)372 (66.1)No. of vessels with significant stenosis, *n* (%) 1517 (38.2)198 (35.2)0.015 2493 (36.4)186 (33.0) 3343 (25.4)179 (31.8)Target vessel, *n* (%) Left main79 (5.8)46 (8.2)0.157 Left anterior desc.701 (51.8)275 (48.8) Left circumflex245 (18.1)94 (16.7) Right coronary artery266 (19.7)114 (20.2) Arterial bypass graft9 (0.7)2 (0.4) Saphenous vein graft53 (3.9)32 (5.7)Extensive calcifications, *n* (%)111 (8.2)56 (9.9)0.200Glycoprotein IIb/IIIa inhibitors, *n* (%)75 (5.5)21 (3.7)0.123Stent thrombosis in culprit lesion, *n* (%)7 (0.5)1 (0.1)0.450Average stent diameter (mm), median (IQR)3.0 (2.5--3.5)3.0 (2.7--3.5)0.729Total stent length (mm), median (IQR)23 (15.0--28.2)22 (15--28)0.423Residual stenosis post-PCI, *n* (%)9 (0.6)8 (1.4)0.108TIMI 3 flow post-PCI, *n* (%)1341 (99.1)554 (98.4)0.173*DES-I* first-generation drug-eluting stents, *DES-II* second-generation drug-eluting stents, *TIMI* thrombosis in myocardial infarction, *PCI* percutaneous coronary intervention

In-hospital outcomes {#Sec7}
--------------------

There was a higher rate of in-hospital bleeding complications requiring blood transfusion in the elderly patients (2.0 vs. 0.9%; *p* = 0.003), compared to the younger aged group (Fig. [1](#Fig1){ref-type="fig"}). Even so, there were no differences in rates of acute and subacute ST in both groups of patients. There were more resuscitated cardiac arrests (2.0 vs. 0.9%; *p* = 0.084) in the elderly patients during hospitalization. The composite in-hospital rate of MACCE did not differ statistically between these two groups (1.4 vs. 1.1%; *p* = 0.567) (Table [4](#Tab4){ref-type="table"}).Fig. 1In-hospital bleeding complications according to the age Table 4In-hospital and 12-month follow-up according to the ageAge \<70\
*n* = 1353 (70.6%)Age ≥70\
*n* = 563 (29.4%)*p*In-hospital adverse events Cardiogenic shock, *n* (%)12 (0.9)6 (1.1)0.912 Respiratory insufficiency, *n* (%)5 (0.4)6 (1.1)0.123 Cardiac arrest, *n* (%)12 (0.9)11 (2.0)0.084 Death, *n* (%)7 (0.5)7 (1.2)0.089 MI, *n* (%)9 (0.6)3 (0.5)0.738 TVR, *n* (%)9 (0.6)2 (0.3)0.413 Stroke, *n* (%)0 (0)0 (0)-- MACCE, *n* (%)15 (1.1)8 (1.4)0.56712-Month adverse events Death, *n* (%)25 (1.8)40 (7.1)\<0.001 MI, *n* (%)66 (4.8)34 (6.0)0.300 TVR, *n* (%)134 (9.9)41 (7.2)0.075 Stroke, *n* (%)9 (0.6)5 (0.8)0.600 MACCE, *n* (%)182 (13.4)85 (15.0)0.324Stent thrombosis Acute, *n* (%)8 (0.6)2 (0.4)0.760 Subacute, *n* (%)5 (0.4)2 (0.4)0.712 Late, *n* (%)3 (0.2)2 (0.3)0.975 Gastrointestinal bleeding events in 12-month follow-up, *n* (%)13 (1.0)9 (1.6)0.338*MI* myocardial infarction, *TVR* target vessel revascularization, *MACCE* major adverse cardiac and cerebral events

12-Month follow-up {#Sec8}
------------------

Although a higher all-cause mortality rate was noted in the elderly patients (7.1 vs. 1.8%, *p* \< 0.001), there were no differences in the frequency of composite MACCE (15.0 vs. 13.4%, *p* = 0.324) at 12-month follow-up. There also were no differences in the frequency of repeated revascularizations (7.2 vs. 9.9%, *p* = 0.075), MI (6.0 vs. 4.8%, *p* = 0.300) and strokes (0.8 vs. 0.6%, *p* = 0.600). Data used for the 12-month MACCE probability were presented using Kaplan--Meier curves stratified according to age (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). Twelve-month cumulative rate of late stent thrombosis did not differ significantly between these two groups of patients (*p* = 0.975). The rate of 12-month follow-up gastrointestinal bleeding was low and did not differ between groups (*p* = 0.338) (Table [4](#Tab4){ref-type="table"}). The multivariable Cox regressions analysis revealed that age ≥70 was the independent predictor of death \[HR = 2.55 (95% CI 1.49--4.37); *p* \< 0.001\] at 12-month follow-up (Table [5](#Tab5){ref-type="table"}).Fig. 2Kaplan--Meier curves for MACCE according to the age Fig. 3Kaplan--Meier curves for death, myocardial infarction, stroke, TVR according to the age Table 5Univariable and multivariable Cox regression analysisPredictors of deathUnivariable analysisMultivariable analysisAge ≥70 y/o1.071.04--1.10\<0.0012.551.49--4.37\<0.001CKD2.722.28--6.06\<0.0012.111.23--3.60\<0.001DM1.981.21--3.21\<0.0011.560.95--2.550.070Anemia2.601.48--4.56\<0.0011.590.89--2.860.116Bleeding with blood transfusion10.384.19--25.75\<0.0014.351.68--11.280.038Neoplasm2.201.05--4.590.0361.650.78--3.840.187CKD was defined as estimated GFR (eGFR) \<60 60 ml/min/1.73 m^2^ calculated using the modification of diet in renal disease (MDRD) method*CKD* chronic kidney disease, *DM* diabetes mellitus

Comparison of first- and second-generation DES in elderly patients {#Sec9}
------------------------------------------------------------------

There was a lower incidence of MI in the elderly patients treated with DES-II as compared to DES-I (6.7 vs. 9.9%, *p* = 0.004), without significant differences in rate of death (7.5 vs. 6.2%, *p* = 0.586), TVR (5.9 vs. 9.9%, *p* = 0.081), stroke (0.5 vs. 1.5%, *p* = 0.216) and MACCE (13.1 vs. 18.8%, *p* = 0.075) at 12-month follow-up. The use of DES-II reduced the risk of MI \[HR = 0.40 (95% CI 0.19 - 0.82); *p* = 0.012\] in the elderly. MI probability was presented using Kaplan--Meier curves and stratified according to DES generation (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Kaplan--Meier curves for myocardial infarction in patients ≥70 y/o (DES-I vs. DES-II)

Discussion {#Sec10}
==========

We were able to observe during this study that a high proportion of patients hospitalized with ACS were age 70 or over. ACS is known as an important risk factor for cardiovascular events. The main results from our current analysis obtained from Katowice--Zabrze registry' data are that elderly patients have higher rates of death in a one-year follow-up study, more bleeding complications post-PCI, requiring blood transfusions despite the fact that they do not have a higher risk of acute, subacute and late stent thrombosis. The presence of both risk factors (age and acute presentation) identified a cohort of patients with a high risk of complications after PCI \[[@CR4], [@CR11], [@CR12]\]. The current study demonstrated some significant differences between patients representing these two age ranges. Similarly to results observed in other analysis, elderly patients from our registry carry a higher risk of adverse events. They have a higher percentage of comorbidities: hypertension, diabetes, chronic kidney disease, chronic obstructive pulmonary disease, heart failure and higher GRACE risk score as compared to younger group \[[@CR13], [@CR14]\]. Our elderly group did not manifest typical angina as would be expected since time to reperfusion in ACS is longer \[[@CR15], [@CR16]\]. Analysis of available angiographic data demonstrated that this population of elderly patients differed regarding the complex coronary atherosclerotic lesions when compared to our younger patient groups. As observed in a study by Rosengren et al. \[[@CR14]\], these patients have more often multivessel disease and more complex PCI such as left main or saphenous vein graft interventions. Moreover, there were also differences in the efficacy of PCI. Dziewierz et al. \[[@CR5]\] analyzed 1650 patients with STEMI and analyzed the outcomes in age strata (\<65, 65--74, 75--84 and ≥85 years). They demonstrated that elderly patients were less likely to achieve TIMI 3 flow and ST-segment resolution after PCI and were more likely to have PCI complications.

It is well known that elderly patients with CAD have a worse prognosis when compared with younger patients \[[@CR5], [@CR14]\]. Moreover, age is an independent predictor of death and MACCE post-PCI \[[@CR17], [@CR18]\]. In this current study, we observed that at 12-month follow-up, rates of death were significantly higher in our elderly patients. However, there were no differences in MACCE. We also observed that elderly patients had more often bleeding complications required a blood transfusion after PCI compared to their younger counterparts. Bleeding is the most frequent non-ischemic complication observed in ACS patients \[[@CR19]\]. In addition to such factors as male sex, chronic kidney disease and anemia, older age also increases the risk of bleeding complications in ACS \[[@CR20]--[@CR23]\]. Therefore, these patients need to have individualized antiplatelet therapy to decrease thrombotic events without increasing bleeding \[[@CR24], [@CR25]\]. Additionally, choosing the best vascular approach during PCI can significantly reduce the risk of bleeding. Radial access is associated with significant reduction in major bleeding and need for blood transfusions \[[@CR26]\].

Stent technology has progressed from bare-metal stents (BMS) to first- and second-generation DES. Data from SCAAR registry indicated that PCI with DES-II was associated with lower risk of clinically significant restenosis, stent thrombosis, and a lower risk of death compared with DES-I in the real-world population \[[@CR27]\]. Limited information is available which compared two types of generational DES used in elderly patients. There were studies, which compared DES with bare-metal stents (BMS) in elderly. de Belder et al. \[[@CR28]\] published data from a randomized multicenter trial, comparing everolimus-eluting stents (EES) with BMS in octogenarian patients with stable angina and ACS. He reported that there were no differences of all-cause death, stroke and bleeding complications. However, use of EES reduced the incidence of MI and TVR in a 1-year follow-up. In our present study, we compared data from DES-I with DES-II used in elderly patients. DES-II was associated with reduced incidence of MI in the following year, but there were no differences in the incidence of death, TVR, stroke or MACCE. Our results confirmed previous observations and, as suggested in ESC guidelines, advocated the use of DES-II for PCI regardless of patient's characteristic \[[@CR29]\].

Study limitations {#Sec11}
=================

Patients were not randomized as to a choice of stent implantation (DES first or second generation), so there was no balance between DES-I and DES-II. There was no information on drugs used before admission to the hospital, especially those with a known impact on the occurrence of bleeding. There was no information about the duration of medication (e.g., patients taking clopidogrel, prasugrel) after PCI.

Conclusion {#Sec12}
==========

Elderly patients had an increased risk of in-hospital bleeding requiring blood transfusion and had a higher risk of death at 12-month follow-up. The use of the new generation of DES reduced the risk of MI in the elderly at 12-month follow-up.
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